Logo image of PRME

PRIME MEDICINE INC (PRME) Stock Fundamental Analysis

NASDAQ:PRME - Nasdaq - US74168J1016 - Common Stock - Currency: USD

3.89  +0.06 (+1.57%)

Fundamental Rating

3

PRME gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. While PRME seems to be doing ok healthwise, there are quite some concerns on its profitability. PRME is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRME had negative earnings in the past year.
PRME had a negative operating cash flow in the past year.
In the past 5 years PRME always reported negative net income.
PRME had a negative operating cash flow in each of the past 5 years.
PRME Yearly Net Income VS EBIT VS OCF VS FCFPRME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

PRME has a Return On Assets of -61.56%. This is comparable to the rest of the industry: PRME outperforms 40.33% of its industry peers.
With a Return On Equity value of -188.93%, PRME is not doing good in the industry: 66.55% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -61.56%
ROE -188.93%
ROIC N/A
ROA(3y)-69.15%
ROA(5y)-55.54%
ROE(3y)-107.23%
ROE(5y)-82.73%
ROIC(3y)N/A
ROIC(5y)N/A
PRME Yearly ROA, ROE, ROICPRME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRME Yearly Profit, Operating, Gross MarginsPRME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

PRME does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRME has been increased compared to 1 year ago.
The number of shares outstanding for PRME has been increased compared to 5 years ago.
There is no outstanding debt for PRME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRME Yearly Shares OutstandingPRME Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PRME Yearly Total Debt VS Total AssetsPRME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PRME has an Altman-Z score of -3.35. This is a bad value and indicates that PRME is not financially healthy and even has some risk of bankruptcy.
PRME has a Altman-Z score (-3.35) which is in line with its industry peers.
PRME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.35
ROIC/WACCN/A
WACC9.83%
PRME Yearly LT Debt VS Equity VS FCFPRME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.78 indicates that PRME has no problem at all paying its short term obligations.
PRME's Current ratio of 4.78 is in line compared to the rest of the industry. PRME outperforms 51.36% of its industry peers.
A Quick Ratio of 4.78 indicates that PRME has no problem at all paying its short term obligations.
The Quick ratio of PRME (4.78) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.78
Quick Ratio 4.78
PRME Yearly Current Assets VS Current LiabilitesPRME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

PRME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.15%, which is quite impressive.
The Revenue has grown by 550.76% in the past year. This is a very strong growth!
EPS 1Y (TTM)26.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
Revenue 1Y (TTM)550.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%146.02%

3.2 Future

Based on estimates for the next years, PRME will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.59% on average per year.
PRME is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 99.72% yearly.
EPS Next Y19.87%
EPS Next 2Y17.23%
EPS Next 3Y12.5%
EPS Next 5Y8.59%
Revenue Next Year542.52%
Revenue Next 2Y265.79%
Revenue Next 3Y218.22%
Revenue Next 5Y99.72%

3.3 Evolution

PRME Yearly Revenue VS EstimatesPRME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2029 2030 2031 2032 200M 400M 600M
PRME Yearly EPS VS EstimatesPRME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRME Price Earnings VS Forward Price EarningsPRME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRME Per share dataPRME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PRME's earnings are expected to grow with 12.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.23%
EPS Next 3Y12.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRME!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRIME MEDICINE INC

NASDAQ:PRME (7/30/2025, 3:56:09 PM)

3.89

+0.06 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners56.55%
Inst Owner Change0.04%
Ins Owners16.29%
Ins Owner Change1.37%
Market Cap523.21M
Analysts81.11
Price Target7.5 (92.8%)
Short Float %21.12%
Short Ratio5.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.02%
Min EPS beat(2)-22.51%
Max EPS beat(2)22.47%
EPS beat(4)1
Avg EPS beat(4)-5.26%
Min EPS beat(4)-22.51%
Max EPS beat(4)22.47%
EPS beat(8)2
Avg EPS beat(8)-9.59%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)340.15%
Min Revenue beat(2)35.89%
Max Revenue beat(2)644.42%
Revenue beat(4)2
Avg Revenue beat(4)120.73%
Min Revenue beat(4)-100%
Max Revenue beat(4)644.42%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-47.03%
EPS NQ rev (1m)0.55%
EPS NQ rev (3m)-11.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.36%
Revenue NQ rev (1m)100%
Revenue NQ rev (3m)31.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)30.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 136.04
P/FCF N/A
P/OCF N/A
P/B 4.89
P/tB 4.89
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0.03
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.56%
ROE -188.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.15%
ROA(5y)-55.54%
ROE(3y)-107.23%
ROE(5y)-82.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 113.5%
Cap/Sales 192.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.78
Quick Ratio 4.78
Altman-Z -3.35
F-Score5
WACC9.83%
ROIC/WACCN/A
Cap/Depr(3y)343.92%
Cap/Depr(5y)671.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
EPS Next Y19.87%
EPS Next 2Y17.23%
EPS Next 3Y12.5%
EPS Next 5Y8.59%
Revenue 1Y (TTM)550.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%146.02%
Revenue Next Year542.52%
Revenue Next 2Y265.79%
Revenue Next 3Y218.22%
Revenue Next 5Y99.72%
EBIT growth 1Y3.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.36%
EBIT Next 3Y7.42%
EBIT Next 5YN/A
FCF growth 1Y19.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.16%
OCF growth 3YN/A
OCF growth 5YN/A